Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide

Journal of Gene Medicine

Volumn 12, Issue 6, 2010, Pages 538-544

  Yanay, Ofer ^a   Moralejo, Daniel ^a,b   Kernan, Kelly ^a   Brzezinski, Margaret ^a   Fuller, Jessica M ^a   Barton, Randall W ^c   Lernmark, Ake ^a   Osborne, William R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Hospital for Special Care New Britain   (United States)

Author keywords

BB rats; Bioisolator; Diabetes; GLP 1; cells

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOBREEDING RAT; CONTROLLED STUDY; DIABETES MELLITUS; ENCAPSULATION; FEMALE; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SURVIVAL; VASCULAR SMOOTH MUSCLE; WEIGHT REDUCTION; ANIMAL; CELL PROLIFERATION; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENETIC TRANSDUCTION; HUMAN; IMPLANT; METABOLISM; PANCREAS; PATHOPHYSIOLOGY; PHYSIOLOGY; SMOOTH MUSCLE FIBER; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IMPLANTS, EXPERIMENTAL; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PANCREAS; RATS; RATS, INBRED BB; RATS, WISTAR; TRANSDUCTION, GENETIC;

EID: 77954574031     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1466     Document Type: Article

References (42)

1. Falorni A, Kockum I, Sanjeevi CB, et al. Pathogenesis of insulin-dependent diabetesmellitus. Bailliere's Clin Endocrinol Met 1995; 9: 25-46.
2. Onkamo P, Vaananen S, Karvonen M, et al. Worldwide increase in incidence of type I diabetes - the analysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-1403.
3. Rubin RR, Peyrot M. Implications of the DCCT. Looking beyond tight control. Diabetes Care 1994; 17: 235-236.
4. Crofford OB. Diabetes control and complications. Ann Rev Med 1995; 46: 267-279.
5. DCCT. The Diabetes Control and Complications Trial Research Group: effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
6. Borch-Johnsen K, Kreiner S, Deckert T. Mortality of type 1 (insulin-dependent) diabetes mellitus in Denmark: a study of relative mortality in 2930 Danish type 1 diabetic patients diagnosed from 1933 to 1972. Diabetologia 1986; 29: 767-772.
7. Mathis D, Vence L, Benoist C. Beta-cell death during progression to diabetes. Nature 2001; 414: 792-798.
8. Kukreja A, Maclaren NK. Autoimmunity and diabetes. J Clin Endocrinol Metab 1999; 84: 4371-4378.
9. Scott J. The spontaneously diabetic BB rat: sites of the defects leading to autoimmunity and diabetes mellitus. A review. Curr Top Microbiol Immunol 1990; 156: 1-14. (Pubitemid 20128707)
10. Mordes JP, Desemone J, Rossini AA. The BB rat. Diabetes Metab Rev 1987; 3: 725-750.
11. Bieg S, Simonson WT, Elefson K, et al. Rel B is an early marker of autoimmune islet inflammation in the biobreeding (BB) rat. Pancreas 2000; 20: 47-54.
12. Bieg S, Koike G, Jiang J, et al. Genetic isolation of the Lyp region on chromosome 4 in the diabetes prone BioBreeding (BB) rat. Mamm Genome 1998; 9: 324-326.
13. MacMurray AJ, Moralejo DH, Kwitek AE, et al. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res 2002; 12: 1029-1039.
14. Shin JH, Janer M, McNeney B, et al. IA-2 autoantibodies in incident type I diabetes patients are associated with a polyadenylation signal polymorphism in GIMAP5. Genes Immun 2007; 8: 185-192.
15. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
16. Deacon CF. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metabol 2007; 9: 23-31.
17. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
18. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16: 390-410.
19. Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem Biophys Res Commun 2002; 294: 1-4.
20. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
21. Holst J. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004; 9: 155-166. (Pubitemid 38715583)
22. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026-1034.
23. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 8: 741-744. (Pubitemid 23218642)
24. Oh S, Lee M, Ko KS, et al. GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther 2003; 7: 478-483.
25. Soltani N, Kumar M, Glinka Y, et al. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin- induced diabetes. Gene Ther 2007; 14: 981-988.
26. Prud'homme GJ, Draghia-Akli R, Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther 2007; 14: 553-564.
27. Lee Y-S, Shin S, Shigihara T, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007; 56: 1671-1679.
28. Parsons GB, Souza DW, Wu H, et al. Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes. Gene Ther 2007; 14: 38-48.
29. Yanay O, Flint LY, Brzezinski M, et al. Long term erythropoietin gene expression from transduced cells in bioisolator devices. Hum Gene Ther 2003; 14: 1587-1593.
30. Sweet IR, Yanay O, Waldron L, et al. Treatment of diabetic rats with encapsulated islets. J Cell Mol Med 2008; 12: 2644-2650.
31. Fuller J, Kwitek AE, Hawkins T, et al. Introgression of F344 rat genomic DNA on BB rat chromosome 4 generates diabetes-resistant lymphopenic BB rats. Diabetes 2006; 55: 3351-3357.
32. HuiH, Yu R, Bousquet C, et al. Transfection of pancreatic-derived beta-cells with a minigene encoding human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion. Endocrinology 2002; 143: 3529-3539.
33. Geary RL, Clowes AW, Lau S, et al. Gene transfer in baboons using prosthetic vascular grafts seeded with retrovirally transduced smooth muscle cells: a model for local and systemic gene therapy. Hum Gene Ther 1994; 5: 1213-1218.
34. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
35. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989; 7: 980-990. (Pubitemid 19262578)
36. Lynch CM, Clowes MM, Osborne WRA, et al. Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: A model for gene therapy. Proc Natl Acad Sci USA 1992; 89: 1138-1142.
37. Taneda S, Segerer S, Hudkins KL, et al. Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice. Am J Pathol 2001; 159: 2355-2369.
38. Ahn Y, Xu G, Marselli L, et al. Changes in gene expression in beta cells after islet isolation and transplantation using laser-capture microdissection. Diabetologia 2007; 50: 334-342.
39. Moralejo DH, Hansen CT, Treuting P, et al. Differential effects of leptin receptor mutation on male and female BBDR. Gimap5-/Gimap5- spontaneously diabetic rats. Physiol Genomics 2010; 41: 9-20.
40. Seppen J, Barry S, Lam GM, et al. Retroviral preparations derived from PA317 packaging cells contain inhibitors that co-purify with viral particles and are devoid of viral vector RNA. Hum Gene Ther 2000; 11: 771-775.
41. Martinic MM, von Herrath MG. Real-time imaging of the pancreas during development of diabetes. Immunol Rev 2008; 221: 200-213.
42. Madsbad S, Alberti KG, Binder C, et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979; 2: 1257-1259.